Physician profile
William R Beam
NPI 1962500199
$2,217.99
in general payments reported to CMS, 2019-2025
30 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 78% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $175 · 2021: $262 · 2022: $28.03 · 2023: $244 · 2024: $199 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,434.68 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $427.57 | 2025 | |
| Harmony Biosciences LLC | $299.20 | 2025 | |
| Axsome Therapeutics, INC. | $297.64 | 2023-2025 | Sunosi |
| Abbvie INC. | $188.09 | 2022-2025 | Ubrelvy |
| Janssen Pharmaceuticals, INC | $164.43 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $119.65 | 2020-2024 | Fasenra, Farxiga |
| Glaxosmithkline, LLC. | $76.97 | 2020-2025 | Nucala, Trelegy Ellipta |
| Vifor Pharma, INC. | $65.10 | 2020-2021 | |
| Angiodynamics, INC. | $59.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.78 | 2019-2020 | |
| Novo Nordisk INC | $48.30 | 2020-2025 | Ozempic |
| Ambu INC. | $46.35 | 2025 | |
| Amgen INC. | $42.47 | 2020-2023 | Tezspire |
| Esperion Therapeutics, INC. | $35.02 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.71 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $28.18 | 2024 | |
| Mylan Specialty L.P. | $27.79 | 2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $24.09 | 2021 | |
| Inspire Medical Systems, INC. | $23.65 | 2023 | Inspire |
| Lilly USA, LLC | $20.95 | 2024 | Jardiance |
| Verona Pharma, INC. | $20.31 | 2025 | Ohtuvayre |
| Regeneron Healthcare Solutions, INC. | $19.42 | 2025 | Dupixent |
| Insmed, INC. | $17.73 | 2025 | Arikayce |
| Baxter Healthcare | $17.39 | 2023 | Starling System |
| Eisai INC. | $13.74 | 2021 | |
| Amarin Pharma, INC. | $12.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.55 | 2021 | |
| Lundbeck LLC | $11.31 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $7.28 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $5.42 | 2023 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Beam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.